Aim: Data from PRIME showed pmab + FOLFOX4 to be an effective and tolerable first-line treatment for patients ( pts) with RAS WT metastatic colorectal cancer (mCRC). However, treatment outcomes can differ in pts of differing age. Methods: PRIME was a randomised (1:1) phase 3 study comparing first-line pmab 6.0 mg/kg Q2W + FOLFOX4 vs FOLFOX4 in mCRC pts. Pts with no mutations in KRAS/ NRAS exons 2, 3 or 4 (including codon 59) were classed as having RAS WT mCRC. In this exploratory analysis conducted when ≥80% of pts had an OS event, efficacy/safety were assessed for RAS WT pts by baseline age (<65, ≥65 and ≤75, >75 years [yr]). Efficacy endpoints assessed were objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). Data were analysed using Cox's proportional hazards models. Results: Overall 505 pts had RAS WT mCRC and 499 pts were included in this analysis of age. Median OS and PFS were longer with pmab + FOLFOX4 vs FOLFOX4 in pts <65 yr (OS: 25.8 vs 21.2 months [mo]; PFS: 12.9 vs 8.7 mo) and also in pts ≥65 yr overall (OS: 26.6 vs 17.4 mo; PFS: 9.7 vs 9.2 mo) [Table] . ORRs were higher in the pmab + FOLFOX4 vs FOLFOX4 arm for pts <65 yr (65% vs 47%) and pts ≥65 yr overall (49% vs 42%). Pmab + FOLFOX4-treated pts ≥65-≤ 75 yr (n = 154) had higher ORRs (57% vs 45%) and longer OS (hazard ratio Conclusions: In subgroup analyses of RAS WT pts from PRIME, pmab + FOLFOX4 appears to offer benefit over FOLFOX4 alone both in pts <65 and ≥65 yr. Analysis of efficacy in the >75 yr population was limited by pt numbers and more research is needed to assess treatment benefit in these pts. Disclosure: J. Douillard: has participated in AMGEN steering committee and symposia (both compensated); S. Siena: has been a member of advisory boards for Amgen, Bayer, Roche, Sanofi-Aventis, and Celgene M. Peeters: has had consultant/advisory roles for Amgen (all compensated) and has also received honoraria and research funding from Amgen; R. Koukakis: is an Amgen Ltd employee and stockholder; J. Terwey: is an Amgen (Europe) GmbH employee and stockholder; J. Tabernero: has participated in Advisory boards for Amgen.
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